{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:20:32Z","timestamp":1794432032162,"version":"4.9.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-73673-1","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T10:14:51Z","timestamp":1780136091000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Tunable gene control via RNA splicing with a clinically approved small molecule"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2592-1881","authenticated-orcid":false,"given":"Mateusz","family":"Mendel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0322-5059","authenticated-orcid":false,"given":"Dominic","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asia","family":"Franceschetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Majcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Venetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8151-8295","authenticated-orcid":false,"given":"Hasane","family":"Ratni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Jagasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0361-4636","authenticated-orcid":false,"given":"Martin","family":"Ebeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7156-2383","authenticated-orcid":false,"given":"Filip","family":"Roudnicky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8150-9928","authenticated-orcid":false,"given":"Lina","family":"Schukur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"73673_CR1","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/s41434-023-00390-5","volume":"30","author":"DB Kohn","year":"2023","unstructured":"Kohn, D. B., Chen, Y. Y. & Spencer, M. J. Successes and challenges in clinical gene therapy. Gene Ther. 30, 738\u2013746 (2023).","journal-title":"Gene Ther"},{"key":"73673_CR2","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1016\/j.ymthe.2025.04.004","volume":"33","author":"GL Butterfield","year":"2025","unstructured":"Butterfield, G. L., Reisman, S. J., Iglesias, N. & Gersbach, C. A. Gene regulation technologies for gene and cell therapy. Mol. Ther. 33, 2104\u20132111 (2025).","journal-title":"Mol. Ther."},{"key":"73673_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ymthe.2005.03.022","volume":"12","author":"S Goverdhana","year":"2005","unstructured":"Goverdhana, S. et al. Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol. Ther. 12, 189\u2013211 (2005).","journal-title":"Mol. Ther."},{"key":"73673_CR4","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adj6251","volume":"10","author":"L Lu","year":"2024","unstructured":"Lu, L., Xie, M., Yang, B., Zhao, W. & Cao, J. Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control. Sci. Adv. 10, eadj6251 (2024).","journal-title":"Sci. Adv."},{"key":"73673_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-med-012017-043332","volume":"70","author":"XM Anguela","year":"2019","unstructured":"Anguela, X. M. & High, K. A. Entering the modern era of gene therapy. Annu. Rev. Med. 70, 1\u201316 (2017).","journal-title":"Annu. Rev. Med."},{"key":"73673_CR6","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1089\/10430340260201707","volume":"13","author":"M Latta-Mahieu","year":"2002","unstructured":"Latta-Mahieu, M. et al. Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression. Hum. Gene Ther. 13, 1611\u20131620 (2002).","journal-title":"Hum. Gene Ther."},{"key":"73673_CR7","doi-asserted-by":"publisher","first-page":"11605","DOI":"10.1128\/JVI.76.22.11605-11611.2002","volume":"76","author":"D Favre","year":"2002","unstructured":"Favre, D. et al. Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus. J. Virol. 76, 11605\u201311611 (2002).","journal-title":"J. Virol."},{"key":"73673_CR8","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1016\/j.ymthe.2023.10.020","volume":"31","author":"IK Lee","year":"2023","unstructured":"Lee, I. K. et al. A genetically encoded protein tag for control and quantitative imaging of CAR T cell therapy. Mol. Ther. 31, 3564\u20133578 (2023).","journal-title":"Mol. Ther."},{"key":"73673_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02460-2","volume":"7","author":"Z Liu","year":"2017","unstructured":"Liu, Z. et al. Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector. Sci. Rep. 7, 2193 (2017).","journal-title":"Sci. Rep."},{"key":"73673_CR10","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/19420862.2015.1008351","volume":"7","author":"J Chng","year":"2015","unstructured":"Chng, J. et al. Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells. mAbs. 7, 403\u2013412 (2015).","journal-title":"mAbs"},{"key":"73673_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/mt.2009.255","volume":"18","author":"Z Wu","year":"2010","unstructured":"Wu, Z., Yang, H. & Colosi, P. Effect of genome size on AAV vector packaging. Mol. Ther. 18, 80\u201386 (2010).","journal-title":"Mol. Ther."},{"key":"73673_CR12","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/gt.2009.81","volume":"16","author":"KH Link","year":"2009","unstructured":"Link, K. H. & Breaker, R. R. Engineering ligand-responsive gene-control elements: lessons learned from natural riboswitches. Gene Ther. 16, 1189\u20131201 (2009).","journal-title":"Gene Ther"},{"key":"73673_CR13","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1021\/acssynbio.4c00731","volume":"14","author":"RW Bruckhoff","year":"2025","unstructured":"Bruckhoff, R. W., Becker, O., Steinhilber, D. & Suess, B. Potential and optimization of mammalian splice riboswitches for the regulation of exon skipping-dependent gene expression and isoform switching within the ALOX5 gene. ACS Synth. Biol. 14, 804\u2013818 (2025).","journal-title":"ACS Synth. Biol."},{"key":"73673_CR14","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nbt.3301","volume":"33","author":"L Wroblewska","year":"2015","unstructured":"Wroblewska, L. et al. Mammalian synthetic circuits with RNA binding proteins for RNA-only delivery. Nat. Biotechnol. 33, 839\u2013841 (2015).","journal-title":"Nat. Biotechnol."},{"key":"73673_CR15","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3390\/ph14060554","volume":"14","author":"ZJ Tickner","year":"2021","unstructured":"Tickner, Z. J. & Farzan, M. Riboswitches for controlled expression of therapeutic transgenes delivered by adeno-associated viral vectors. Pharmaceuticals 14, 554 (2021).","journal-title":"Pharmaceuticals"},{"key":"73673_CR16","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1038\/s41587-023-01989-0","volume":"42","author":"L Luo","year":"2024","unstructured":"Luo, L., Jea, J. D.-Y., Wang, Y., Chao, P.-W. & Yen, L. Control of mammalian gene expression by modulation of polyA signal cleavage at 5\u2032 UTR. Nat. Biotechnol. 42, 1454\u20131466 (2024).","journal-title":"Nat. Biotechnol."},{"key":"73673_CR17","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41586-021-03770-2","volume":"596","author":"AM Monteys","year":"2021","unstructured":"Monteys, A. M. et al. Regulated control of gene therapies by drug-induced splicing. Nature 596, 291\u2013295 (2021).","journal-title":"Nature"},{"key":"73673_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2024.100842","volume":"4","author":"Y Chi","year":"2024","unstructured":"Chi, Y. et al. A compact, versatile drug-induced splicing switch system with minimal background expression. Cell Rep. Methods 4, 100842 (2024).","journal-title":"Cell Rep. Methods"},{"key":"73673_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28653-6","volume":"13","author":"CG Keller","year":"2022","unstructured":"Keller, C. G. et al. An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion. Nat. Commun. 13, 1150 (2022).","journal-title":"Nat. Commun."},{"key":"73673_CR20","doi-asserted-by":"publisher","first-page":"11021","DOI":"10.1021\/acs.jmedchem.8b01291","volume":"61","author":"AK Cheung","year":"2018","unstructured":"Cheung, A. K. et al. Discovery of small molecule splicing modulators of Survival Motor Neuron\u20112 (SMN2) for the treatment of Spinal Muscular Atrophy (SMA). J. Med. Chem. 61, 11021\u201311036 (2018).","journal-title":"Med. Chem."},{"key":"73673_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41591-025-04117-4","volume":"32","author":"B Borowsky","year":"2026","unstructured":"Borowsky, B. et al. Oral splicing modulator branaplam in Huntington\u2019s disease: a phase 2 randomized controlled trial. Nat. Med. 32, 103\u2013112 (2026).","journal-title":"Nat. Med."},{"key":"73673_CR22","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/s44161-025-00665-7","volume":"4","author":"Z Chen","year":"2025","unstructured":"Chen, Z. et al. The drug-elicitable alternative splicing module for tunable vector expression in the heart. Nat. Cardiovasc. Res. 4, 938\u2013955 (2025).","journal-title":"Nat. Cardiovasc. Res."},{"key":"73673_CR23","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","volume":"61","author":"H Ratni","year":"2018","unstructured":"Ratni, H. et al. Discovery of risdiplam, a selective Survival of Motor Neuron-2 (SMN2) gene splicing modifier for the treatment of Spinal Muscular Atrophy (SMA). J. Med. Chem. 61, 6501\u20136517 (2018).","journal-title":"J. Med. Chem."},{"key":"73673_CR24","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1093\/nar\/gkae201","volume":"52","author":"F Malard","year":"2024","unstructured":"Malard, F. et al. The diversity of splicing modifiers acting on A-1 bulged 5\u2032-splice sites reveals rules for rational drug design. Nucleic Acids Res. 52, 4124\u20134136 (2024).","journal-title":"Nucleic Acids Res"},{"key":"73673_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46090-5","volume":"15","author":"Y Ishigami","year":"2024","unstructured":"Ishigami, Y. et al. Specificity, synergy, and mechanisms of splice-modifying drugs. Nat. Commun. 15, 1880 (2024).","journal-title":"Nat. Commun."},{"key":"73673_CR26","doi-asserted-by":"publisher","first-page":"R111","DOI":"10.1093\/hmg\/ddq147","volume":"19","author":"CL Lorson","year":"2010","unstructured":"Lorson, C. L., Rindt, H. & Shababi, M. Spinal muscular atrophy: mechanisms and therapeutic strategies. Hum. Mol. Genet. 19, R111\u2013R118 (2010).","journal-title":"Hum. Mol. Genet."},{"key":"73673_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre, S. et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155\u2013165 (1995).","journal-title":"Cell"},{"key":"73673_CR28","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","volume":"96","author":"CL Lorson","year":"1999","unstructured":"Lorson, C. L., Hahnen, E., Androphy, E. J. & Wirth, B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl. Acad. Sci. U.S.A. 96, 6307\u20136311 (1999).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"73673_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nature10485","volume":"478","author":"Y Hua","year":"2011","unstructured":"Hua, Y. et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 478, 123\u2013126 (2011).","journal-title":"Nature"},{"key":"73673_CR30","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1021\/acsmedchemlett.0c00659","volume":"12","author":"H Ratni","year":"2021","unstructured":"Ratni, H., Scalco, R. S. & Stephan, A. H. Risdiplam, the first approved small molecule splicing modifier drug as a blueprint for future transformative medicines. ACS Med. Chem. Lett. 12, 874\u2013877 (2021).","journal-title":"ACS Med. Chem. Lett."},{"key":"73673_CR31","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2102047","volume":"385","author":"BT Darras","year":"2021","unstructured":"Darras, B. T. et al. Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N. Engl. J. Med. 385, 427\u2013435 (2021).","journal-title":"N. Engl. J. Med."},{"key":"73673_CR32","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/bcp.13786","volume":"85","author":"S Sturm","year":"2019","unstructured":"Sturm, S. et al. A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier. Br. J. Clin. Pharmacol. 85, 181\u2013193 (2019).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"73673_CR33","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41392-024-01809-0","volume":"9","author":"J Cerneckis","year":"2024","unstructured":"Cerneckis, J., Cai, H. & Shi, Y. Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications. Signal Transduct. Target. Ther. 9, 112 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"73673_CR34","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.devcel.2016.01.024","volume":"36","author":"DK Goode","year":"2016","unstructured":"Goode, D. K. et al. Dynamic gene regulatory networks drive hematopoietic specification and differentiation. Dev. Cell 36, 572\u2013587 (2016).","journal-title":"Dev. Cell"},{"key":"73673_CR35","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.cell.2014.07.020","volume":"158","author":"P Cahan","year":"2014","unstructured":"Cahan, P. et al. CellNet: Network biology applied to stem cell engineering. Cell 158, 903\u2013915 (2014).","journal-title":"Cell"},{"key":"73673_CR36","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.cell.2008.02.008","volume":"132","author":"CE Murry","year":"2008","unstructured":"Murry, C. E. & Keller, G. Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell 132, 661\u2013680 (2008).","journal-title":"Cell"},{"key":"73673_CR37","doi-asserted-by":"publisher","first-page":"266","DOI":"10.12688\/openreseurope.19024.1","volume":"4","author":"M Guichardaz","year":"2024","unstructured":"Guichardaz, M., Bottini, S., Balmas, E. & Bertero, A. Overcoming the silencing of doxycycline-inducible promoters in hIPSC-derived cardiomyocytes. Open Res. Eur. 4, 266 (2024).","journal-title":"Open Res. Eur."},{"key":"73673_CR38","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.1038\/mtna.2015.37","volume":"4","author":"X-H Zhang","year":"2015","unstructured":"Zhang, X.-H., Tee, L. Y., Wang, X.-G., Huang, Q.-S. & Yang, S.-H. Off-target effects in CRISPR\/Cas9-mediated genome engineering. Mol. Ther. Nucleic Acids 4, e264 (2015).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"73673_CR39","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris, E. C., Neelapu, S. S., Giavridis, T. & Sadelain, M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat. Rev. Immunol. 22, 85\u201396 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"73673_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1057-4","volume":"18","author":"S Yu","year":"2019","unstructured":"Yu, S., Yi, M., Qin, S. & Wu, K. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Mol. Cancer 18, 125 (2019).","journal-title":"Mol. Cancer"},{"key":"73673_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01559-4","volume":"8","author":"M Sivaramakrishnan","year":"2017","unstructured":"Sivaramakrishnan, M. et al. Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers. Nat. Commun. 8, 1476 (2017).","journal-title":"Nat. Commun."},{"key":"73673_CR42","doi-asserted-by":"publisher","first-page":"617842","DOI":"10.1155\/2014\/617842","volume":"2014","author":"S Cho","year":"2014","unstructured":"Cho, S. et al. 3\u2032 splice site sequences of spinal muscular atrophy related SMN2 pre-mRNA include enhancers for nearby exons. Sci. World J. 2014, 617842 (2014).","journal-title":"Sci. World J."},{"key":"73673_CR43","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1038\/sj.gt.3301550","volume":"8","author":"M Zhang","year":"2001","unstructured":"Zhang, M., Lorson, C., Androphy, E. & Zhou, J. An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA. Gene Ther 8, 1532\u20131538 (2001).","journal-title":"Gene Ther"},{"key":"73673_CR44","doi-asserted-by":"publisher","first-page":"16176","DOI":"10.1073\/pnas.0508489102","volume":"102","author":"KL Fox-Walsh","year":"2005","unstructured":"Fox-Walsh, K. L. et al. The architecture of pre-mRNAs affects mechanisms of splice-site pairing. Proc. Natl. Acad. Sci. USA. 102, 16176\u201316181 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"73673_CR45","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-3-319-89689-2_2","volume":"20","author":"RN Singh","year":"2018","unstructured":"Singh, R. N. & Singh, N. N. Mechanism of Splicing Regulation of Spinal Muscular Atrophy Genes. Adv. Neurobiol. 20, 31\u201361 (2018).","journal-title":"Adv. Neurobiol."},{"key":"73673_CR46","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","volume":"8","author":"UR Monani","year":"1999","unstructured":"Monani, U. R. et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum. Mol. Genet. 8, 1177\u20131183 (1999).","journal-title":"Hum. Mol. Genet."},{"key":"73673_CR47","doi-asserted-by":"publisher","first-page":"194403","DOI":"10.1016\/j.bbagrm.2019.07.004","volume":"1862","author":"NN Singh","year":"2019","unstructured":"Singh, N. N. & Singh, R. N. How RNA structure dictates the usage of a critical exon of spinal muscular atrophy gene. Biochim. Biophys. Acta (BBA) - Gene Regul. Mech. 1862, 194403 (2019).","journal-title":"Biochim. Biophys. Acta (BBA) - Gene Regul. Mech."},{"key":"73673_CR48","doi-asserted-by":"publisher","first-page":"MSB145136","DOI":"10.15252\/msb.20145136","volume":"10","author":"WL Noderer","year":"2014","unstructured":"Noderer, W. L. et al. Quantitative analysis of mammalian translation initiation sites by FACS-seq. Mol. Syst. Biol. 10, MSB145136 (2014).","journal-title":"Mol. Syst. Biol."},{"key":"73673_CR49","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1101\/gad.305250.117","volume":"31","author":"MG Kearse","year":"2017","unstructured":"Kearse, M. G. & Wilusz, J. E. Non-AUG translation: a new start for protein synthesis in eukaryotes. Genes Dev. 31, 1717\u20131731 (2017).","journal-title":"Genes Dev"},{"key":"73673_CR50","doi-asserted-by":"publisher","first-page":"18056","DOI":"10.1073\/pnas.1009269107","volume":"107","author":"IP Ivanov","year":"2010","unstructured":"Ivanov, I. P., Loughran, G., Sachs, M. S. & Atkins, J. F. Initiation context modulates autoregulation of eukaryotic translation initiation factor 1 (eIF1). Proc. Natl. Acad. Sci. USA. 107, 18056\u201318060 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"73673_CR51","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1126\/science.1168978","volume":"324","author":"NT Ingolia","year":"2009","unstructured":"Ingolia, N. T., Ghaemmaghami, S., Newman, J. R. S. & Weissman, J. S. Genome-wide analysis in vivo of translation with nucleotide resolution using ribosome profiling. Science 324, 218\u2013223 (2009).","journal-title":"Science"},{"key":"73673_CR52","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.stemcr.2021.11.015","volume":"17","author":"AJ Hulme","year":"2021","unstructured":"Hulme, A. J., Maksour, S., Glover, M. S.-C., Miellet, S. & Dottori, M. Making neurons, made easy: The use of Neurogenin-2 in neuronal differentiation. Stem Cell Rep. 17, 14\u201334 (2021).","journal-title":"Stem Cell Rep"},{"key":"73673_CR53","doi-asserted-by":"publisher","first-page":"e12413","DOI":"10.1371\/journal.pone.0012413","volume":"5","author":"K Norrman","year":"2010","unstructured":"Norrman, K. et al. Quantitative comparison of constitutive promoters in human ES cells. PLoS ONE 5, e12413 (2010).","journal-title":"PLoS ONE"},{"key":"73673_CR54","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1089\/scd.2006.0057","volume":"16","author":"X Xia","year":"2007","unstructured":"Xia, X., Zhang, Y., Zieth, C. R. & Zhang, S.-C. Transgenes delivered by lentiviral vector are suppressed in human embryonic stem cells in a promoter-dependent manner. Stem Cells Dev. 16, 167\u2013176 (2007).","journal-title":"Stem Cells Dev."},{"key":"73673_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2024.100858","volume":"4","author":"X Shan","year":"2024","unstructured":"Shan, X. et al. Fully defined NGN2 neuron protocol reveals diverse signatures of neuronal maturation. Cell Rep. Methods 4, 100858 (2024).","journal-title":"Cell Rep. Methods"},{"key":"73673_CR56","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1093\/nar\/gkr1251","volume":"40","author":"M Gitzinger","year":"2012","unstructured":"Gitzinger, M. et al. The food additive vanillic acid controls transgene expression in mammalian cells and mice. Nucleic Acids Res. 40, e37 (2012).","journal-title":"Nucleic Acids Res"},{"key":"73673_CR57","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.4161\/auto.26501","volume":"9","author":"G Hernandez","year":"2013","unstructured":"Hernandez, G. et al. MitoTimer: a novel tool for monitoring mitochondrial turnover. Autophagy 9, 1852\u20131861 (2013).","journal-title":"Autophagy"},{"key":"73673_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 11, 69 (2021).","journal-title":"Blood Cancer J"},{"key":"73673_CR59","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","volume":"26","author":"Q Deng","year":"2020","unstructured":"Deng, Q. et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat. Med. 26, 1878\u20131887 (2020).","journal-title":"Nat. Med."},{"key":"73673_CR60","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","volume":"4","author":"FL Locke","year":"2020","unstructured":"Locke, F. L. et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 4, 4898\u20134911 (2020).","journal-title":"Blood Adv"},{"key":"73673_CR61","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1158\/1078-0432.CCR-22-0164","volume":"28","author":"C Monfrini","year":"2022","unstructured":"Monfrini, C. et al. Phenotypic composition of commercial anti-CD19 CAR-T cells affects in vivo expansion and disease response in large B-cell lymphoma patients. Clin. Cancer Res. 28, 3378\u20133386 (2022).","journal-title":"Clin. Cancer Res."},{"key":"73673_CR62","first-page":"4939","volume":"13","author":"CWJ Smith","year":"1993","unstructured":"Smith, C. W. J., Chu, T. T. & Nadal-Ginard, B. Scanning and competition between AGs are involved in 3\u2019 splice site selection in mammalian introns. Mol. Cell. Biol. 13, 4939\u20134952 (1993).","journal-title":"Mol. Cell. Biol."},{"key":"73673_CR63","doi-asserted-by":"publisher","first-page":"9243","DOI":"10.1073\/pnas.86.23.9243","volume":"86","author":"PD Zamore","year":"1989","unstructured":"Zamore, P. D. & Green, M. R. Identification, purification, and biochemical characterization of U2 small nuclear ribonucleoprotein auxiliary factor. Proc. Natl. Acad. Sci. USA. 86, 9243\u20139247 (1989).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"73673_CR64","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1126\/science.273.5282.1706","volume":"273","author":"J Valc\u00e1rcel","year":"1996","unstructured":"Valc\u00e1rcel, J., Gaur, R. K., Singh, R. & Green, M. R. Interaction of U2AF65 RS region with pre-mRNA of branch point and promotion base pairing with U2 snRNA. Science 273, 1706\u20131709 (1996).","journal-title":"Science"},{"key":"73673_CR65","doi-asserted-by":"publisher","first-page":"11456","DOI":"10.1073\/pnas.94.21.11456","volume":"94","author":"P Cramer","year":"1997","unstructured":"Cramer, P., Pesce, C. G., Baralle, F. E. & Kornblihtt, A. R. Functional association between promoter structure and transcript alternative splicing. Proc. Natl. Acad. Sci. USA. 94, 11456\u201311460 (1997).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"73673_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39200-2","volume":"14","author":"M Uriostegui-Arcos","year":"2023","unstructured":"Uriostegui-Arcos, M., Mick, S. T., Shi, Z., Rahman, R. & Fiszbein, A. Splicing activates transcription from weak promoters upstream of alternative exons. Nat. Commun. 14, 3435 (2023).","journal-title":"Nat. Commun."},{"key":"73673_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-67201-w","volume":"17","author":"R Srinivasan","year":"2026","unstructured":"Srinivasan, R. et al. Chemically-inducible CRISPR\/Cas9 circuits for ultra-high dynamic range gene perturbation. Nat. Commun. 17, 504 (2025).","journal-title":"Nat. Commun."},{"key":"73673_CR68","doi-asserted-by":"publisher","first-page":"5948","DOI":"10.1093\/nar\/gkad259","volume":"51","author":"EW Ottesen","year":"2023","unstructured":"Ottesen, E. W. et al. Diverse targets of SMN2-directed splicing-modulating small molecule therapeutics for spinal muscular atrophy. Nucleic Acids Res. 51, 5948\u20135980 (2023).","journal-title":"Nucleic Acids Res"},{"key":"73673_CR69","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","volume":"25","author":"CT Charlesworth","year":"2019","unstructured":"Charlesworth, C. T. et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat. Med. 25, 249\u2013254 (2019).","journal-title":"Nat. Med."},{"key":"73673_CR70","doi-asserted-by":"publisher","first-page":"1188049","DOI":"10.3389\/fimmu.2023.1188049","volume":"14","author":"A Mitra","year":"2023","unstructured":"Mitra, A. et al. From bench to bedside: the history and progress of CAR T cell therapy. Front. Immunol. 14, 1188049 (2023).","journal-title":"Front. Immunol."},{"key":"73673_CR71","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","volume":"33","author":"KK Patel","year":"2025","unstructured":"Patel, K. K., Tariveranmoshabad, M., Kadu, S., Shobaki, N. & June, C. From concept to cure: the evolution of CAR-T cell therapy. Mol. Ther. 33, 2123\u20132140 (2025).","journal-title":"Mol. Ther."},{"key":"73673_CR72","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature 543, 113\u2013117 (2017).","journal-title":"Nature"},{"key":"73673_CR73","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba1786","volume":"372","author":"EW Weber","year":"2021","unstructured":"Weber, E. W. et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science 372, eaba1786 (2021).","journal-title":"Science"},{"key":"73673_CR74","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.omtm.2020.10.011","volume":"19","author":"SN Mathiesen","year":"2020","unstructured":"Mathiesen, S. N., Lock, J. L., Schoderboeck, L., Abraham, W. C. & Hughes, S. M. CNS transduction benefits of AAV-PHP.eB over AAV9 are dependent on administration route and mouse strain. Mol. Ther. Methods Clin. Dev. 19, 447\u2013458 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"73673_CR75","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/mt.2008.76","volume":"16","author":"C Zincarelli","year":"2008","unstructured":"Zincarelli, C., Soltys, S., Rengo, G. & Rabinowitz, J. E. Analysis of AAV serotypes 1\u20139 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16, 1073\u20131080 (2008).","journal-title":"Mol. Ther."},{"key":"73673_CR76","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/gt.2016.88","volume":"24","author":"DL Browning","year":"2017","unstructured":"Browning, D. L. et al. Evidence for the in vivo safety of insulated foamy viral vectors. Gene Ther. 24, 187\u2013198 (2017).","journal-title":"Gene Ther"},{"key":"73673_CR77","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/978-1-61779-095-9_8","volume":"737","author":"M Giry-Laterri\u00e8re","year":"2011","unstructured":"Giry-Laterri\u00e8re, M., Verhoeyen, E. & Salmon, P. Viral Vectors for Gene Therapy, Methods and Protocols. Methods Mol. Biol. 737, 183\u2013209 (2011).","journal-title":"Methods Mol. Biol."},{"key":"73673_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.58","volume":"3","author":"R Myburgh","year":"2014","unstructured":"Myburgh, R. et al. Optimization of Critical Hairpin Features Allows miRNA-based gene knockdown upon single-copy transduction. Mol. Ther. Nucleic Acids 3, e207 (2014).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"73673_CR79","first-page":"E2279","volume":"110","author":"X Li","year":"2013","unstructured":"Li, X. et al. piggyBac transposase tools for genome engineering. Proc. Natl. Acad. Sci. USA. 110, E2279\u2013E2287 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"73673_CR80","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2144\/btn-2018-0058","volume":"65","author":"SJ Coulter","year":"2018","unstructured":"Coulter, S. J. Mitigation of the effect of variability in digital PCR assays through use of duplexed reference assays for normalization. BioTechniques 65, 86\u201391 (2018).","journal-title":"BioTechniques"},{"key":"73673_CR81","doi-asserted-by":"publisher","first-page":"5735","DOI":"10.1016\/j.csbj.2021.10.020","volume":"19","author":"KA Mullan","year":"2021","unstructured":"Mullan, K. A. et al. ggVolcanoR: A Shiny app for customizable visualization of differential expression datasets. Comput. Struct. Biotechnol. J. 19, 5735\u20135740 (2021).","journal-title":"Comput. Struct. Biotechnol. J."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73673-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73673-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73673-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:01:52Z","timestamp":1784764912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73673-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["73673"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-73673-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study is supported by F. Hoffmann-La Roche Ltd and Genentech Inc. M.M., D.S., T.S., S.T., A.F., D.M., S.L., D.V., H.R., R.J., M.E., F.R., and L.S. were employees, master or PhD students of F. Hoffmann-La Roche at the time of performing the research. H.R. is currently employed at Skyhawk Therapeutics (Switzerland). D.S. and S.L. were supported by the F. Hoffmann-La Roche doctoral fellowship.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7011"}}